China Shineway Pharmaceutical Group Limited (CSWYY)
Full history for every metric is available with a Kvantra account
China Shineway Pharmaceutical Group Limited (CSWYY)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 2,656 | 3,182 | 4,020 | 4,517 | 3,778 | 3,050 | 2,623 | 2,344 |
| Operating profit | CNY m | 663 | 641 | ||||||
| Net profit | CNY m | 295 | 557 | 723 | 970 | 840 | 924 | 793 | - |
| EPS reported | CNY | 489.4 | 420.6 | ||||||
| Operating cashflow per share | CNY | 620.6 | 33.33 | ||||||
| Capex per share | CNY | 104.8 | 5.25 | ||||||
| FCF per share | CNY | 515.8 | 28.09 | ||||||
| Free cash flow | CNY m | 974 | 1,177 | ||||||
| Net debt | CNY m | -7,245 | -7,229 | ||||||
| Book value equity | CNY m | 8,067 | 8,209 | ||||||
| Book value per share | CNY | 4,272 | 4,347 | ||||||
| Number of shares | m | 1.89 | 1.89 | ||||||
| DPS (TTM paid) | CNY | 9.75 | 40.04 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 0.28 | - | ||||||
| P/B LTM | x | 0.03 | 0.03 | ||||||
| P/S LTM | x | 0.08 | 0.10 | ||||||
| P/FCF LTM | x | 0.26 | 0.22 | ||||||
| EV/EBITDA LTM | x | -9.02 | -8.39 | ||||||
| EV/Sales LTM | x | -2.17 | -0.72 | ||||||
| Earnings Yield LTM | % | +357.14% | +14.97% | ||||||
| FCF Yield | % | +383.20% | +462.96% | ||||||
| Quality | |||||||||
| ROE | % | +11.45% | +9.81% | ||||||
| ROIC | % | +5.77% | +5.63% | ||||||
| Operating margin | % | +21.75% | +24.41% | ||||||
| Gross margin | % | +72.28% | +71.27% | ||||||
| FCF/Sales | % | +31.94% | +40.07% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +10.23% | -5.27% | ||||||
| Sales Growth YoY | % | -19.27% | -30.56% | ||||||
| Net Income Growth YoY | % | +10.00% | -5.59% | ||||||
| FCF Growth | % | +18.36% | +42.99% | ||||||
| Operating Profit Growth | % | -21.26% | -23.89% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +139.67% | +7.35% | ||||||
| Dividend Growth | % | +15.13% | +372.74% | ||||||
| Payout Ratio | % | +38.41% | +38.42% | ||||||
| FCF/Debt | x | 2.91 | 3.77 | ||||||
| Net Debt/EBITDA | x | -9.36 | -9.13 | ||||||
| EBIT/Net interest | x | 119.98 | 296.33 | ||||||
| Net debt/market cap | % | +1.28% | +5.85% | ||||||
| Net debt/Equity | x | -0.90 | -0.88 | ||||||
| Gross debt/equity | x | 0.04 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
As an investment holding company, China Shineway Pharmaceutical Group Limited primarily focuses on the research, development, production, and commercialization of traditional Chinese medicines across mainland China and Hong Kong. Its product portfolio encompasses contemporary Chinese medicines delivered as soft capsules, granules, and injectable solutions. Additionally, it provides specialized TCM Formula Granules, addressing a broad spectrum of medical conditions such as cardiovascular and cerebrovascular issues, viral infections, orthopedic complaints, pediatric ailments, gynecological disorders, and gastrointestinal problems. Beyond pharmaceuticals, the group also engages in the trading of agricultural commodities. Established in 2004, China Shineway Pharmaceutical Group Limited maintains its corporate headquarters in Shijiazhuang, within the People's Republic of China. The company operates as a subsidiary under the umbrella of Forway Investment Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
China Shineway Pharmaceutical Group Limited (CSWYY)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
As an investment holding company, China Shineway Pharmaceutical Group Limited primarily focuses on the research, development, production, and commercialization of traditional Chinese medicines across mainland China and Hong Kong. Its product portfolio encompasses contemporary Chinese medicines delivered as soft capsules, granules, and injectable solutions. Additionally, it provides specialized TCM Formula Granules, addressing a broad spectrum of medical conditions such as cardiovascular and cerebrovascular issues, viral infections, orthopedic complaints, pediatric ailments, gynecological disorders, and gastrointestinal problems. Beyond pharmaceuticals, the group also engages in the trading of agricultural commodities. Established in 2004, China Shineway Pharmaceutical Group Limited maintains its corporate headquarters in Shijiazhuang, within the People's Republic of China. The company operates as a subsidiary under the umbrella of Forway Investment Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free